Effects of fenugreek seed extract on luteinizing and follicle-stimulating hormones in women with polycystic ovary syndrome: a randomized controlled trial
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by reproductive and metabolic disturbances, including an elevated luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratio. Fenugreek seed extract has shown potential in modulating hormonal imbalance in PCOS. The purpose of this study is to examine the effect of fenugreek extract in LH and FSH of women with PCOS.
A randomized controlled trial including 150 women with PCOS was conducted. Participants were divided into three groups, with 50 women in each group: Experimental Group 1 (fenugreek + metformin), Experimental Group 2 (fenugreek only) and Control (metformin only). Randomization was performed using a computer-generated random sequence with allocation concealment through sealed opaque envelopes. Hormonal measurements were taken at baseline and monthly. Statistical analysis included repeated-measures ANOVA with Bonferroni correction, effect sizes and 95% confidence intervals.
Baseline hormonal parameters did not differ significantly between the groups (p > 0.05). After three months of intervention, Group E1 exhibited significant reductions in LH levels (from 11.108 ± 0.52 to 11.469 ± 2.53; p < 0.05), a significant increase in FSH levels (from 3.087 ± 0.12 to 4.615 ± 0.16; p < 0.05) and a marked decrease in the LH/FSH ratio (from 3.79 ± 0.88 to 2.52 ± 0.64; p < 0.05), when compared with Group E2 and the Control group. No major adverse effects were reported.
To evaluate the effects of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 150 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.